Latest Lanthanum carbonate Stories
Drugs commonly prescribed to patients with chronic kidney disease (CKD) may not be as strongly effective as once thought, and may cause unexpected harm to blood vessels.
DUBLIN, October 28 /PRNewswire-FirstCall/ -- - FOSRENOL(R) (lanthanum carbonate) Now Approved in the EU to Treat hyperphosphataemia >1.78mmol/L in Chronic Kidney Disease Patients Not on Dialysis Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, today announced it has received approval through the European Mutual Recognition Procedure for an extension to the current indication for FOSRENOL(R) (lanthanum carbonate), paving the way to make the...
DUBLIN, October 7 /PRNewswire-FirstCall/ -- - For Medical and Healthcare Media Only - - Direct Comparison of the Two non-Calcium Phosphate Binders Gives new Insights Into Relative Efficacy Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, today announces the publication in Clinical Nephrology of findings from a head-to-head clinical study comparing the efficacy of two non-calcium based phosphate binders, FOSRENOL(R) (lanthanum carbonate) and...
PHILADELPHIA, Pennsylvania and DUBLIN, Ireland, February 9 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY), announces that it has received Paragraph IV Notice letters from Barr Laboratories, Inc. ("Barr) and Mylan, Inc.
A New York doctor's sloppy penmanship put a patient's health at risk when he was given the incorrect medication for several months, a lawsuit contends.
PHILADELPHIA, April 3, 2008 /PRNewswire/ -- Shire Pharmaceuticals, the global biopharmaceutical company, today announced the launch of On Track, an innovative program designed to improve adherence to disease management regimens among chronic kidney disease (CKD) Stage 5 patients with hyperphosphatemia (elevated levels of phosphorus in the blood).
- The governor of a province or people.